Rockville Newswire

Comprehensive Real-Time News Feed for Rockville, MD.

Results 1 - 20 of 23 for "u:biospace.com" in Rockville, MD

  1. RegenRx And G-treeBNT Create Joint Venture To Develop RGN-259 In The U.S.Read the original story

    Yesterday | BioSpace

    ROCKVILLE, Md., Jan. 28, 2015 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. today announced that it has entered into agreements with G-treeBNT Co. Ltd., to develop RGN-259 for dry eye syndrome and neurotrophic keratitis in the United States.

    Comment?

  2. ABL Selected To Support Glioblastoma Multiforme Trial With Clinical Testing ServicesRead the original story

    Monday Jan 19 | BioSpace

    ABL, Inc., a contract research and manufacturing organization to the biotechnology and pharmaceutical industry, is pleased to announce that its GCLP clinical laboratory team was recently selected to provide sample processing and screening services in support of a Ph II glioblastoma multiforme immunotherapy trial for a confidential client. ABL will conduct sample processing to isolate peripheral blood mononuclear cells , screen subject samples to identify antigen-specific responders and provide long-term sample storage.

    Comment?

  3. Lockheed Martin Corporation And Illumina To Collaborate On Developing ...Read the original story

    Monday Jan 12 | BioSpace

    ROCKVILLE, Md. & SAN DIEGO-- --Lockheed Martin and Illumina, Inc. today announced a new strategic alliance to collaborate on scalable and affordable genomics solutions to provide personalized health care for national populations.

    Comment?

  4. Emergent BioSolutions To Participate In January 2015 Investor ConferencesRead the original story

    Tuesday Jan 6 | BioSpace

    ROCKVILLE, Md., Jan. 7, 2015 -- Emergent BioSolutions Inc. announced today that a member of the company's senior management team will participate in the following investor conferences in January 2015: The company will be webcasting its participation in these conferences, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcasts will be available both live and by replay, accessible from the Emergent website www.emergentbiosolutions.com under " Investors ."

    Comment?

  5. Scheer Partners, Inc. Lands As Tenant At 2200 Research Boulevard,...Read the original story

    Monday Jan 5 | BioSpace

    NeoImmuneTech, Inc. is moving its Germantown facility to Rockville. Scheer Partners, the leading provider of fully integrated commercial real estate services in the Washington and Baltimore metropolitan areas, announced today that it has secured NeoImmuneTech, Inc. as a tenant at 2200 Research Boulevard, where it will occupy almost 2,000 square feet.

    Comment?

  6. Johnson & Johnson Bets $700 Million On MacroGenics, Inc.'s Blood Cancer DrugRead the original story

    Dec 21, 2014 | BioSpace

    Macrogenics Enters Collaboration And License Agreement With Janssen To Develop MGD011 For Multiple B-Cell Malignancies * MacroGenics licenses MGD011 to Janssen * $50 million upfront license fee paid to MacroGenics, and a $75 million equity investment by Johnson & Johnson Innovation - JJDC, Inc. * MacroGenics may elect to fund a portion of late-stage development costs in exchange for a U.S. and Canada profit share * MacroGenics may elect to co-promote in the United States Rockville, Maryland, Dec. 22, 2014 -- MacroGenics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases, today announced a global collaboration and license agreement for MGD011 with Janssen Biotech, Inc. This product candidate incorporates ... (more)

    Comment?

  7. BeneVir Biopharm, Inc. Announces Investment From HC2 's Subsidiary Pansend, LLCRead the original story

    Nov 23, 2014 | BioSpace

    BeneVir Biopharm, Inc., a biotechnology company developing a pipeline of cancer immunotherapies, today announced it closed a Series A investment round with Pansend, LLC, an indirect wholly owned subsidiary of HC2 Holdings, Inc. . BeneVir's core technology was licensed from New York University and originally developed by Ian J. Mohr, Ph.D., NYU Langone Medical Center.

    Comment?

  8. Emergent BioSolutions To Webcast Presentation At 25th Annual Oppenheimer Healthcare ConferenceRead the original story

    Nov 23, 2014 | BioSpace

    ROCKVILLE, Md., Nov. 24, 2014 -- Emergent BioSolutions Inc. announced today that the company will be webcasting its presentation at the 25TH Annual Oppenheimer Healthcare Conference in New York on Wednesday, December 10, 2014 at 2:45 PM Eastern. During the presentation, a member of the company's management team will provide a corporate overview, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance.

    Comment?

  9. SOTIO Initiates US Part Of VIABLE, A Global Phase III Clinical Trial...Read the original story

    Nov 18, 2014 | BioSpace

    SOTIO, a biotechnology company owned by the PPF Group, today announced that the first US patient has been enrolled in its VIABLE study, the global Phase III clinical trial for DCVAC/PCa, an active cellular immunotherapy treatment for prostate cancer patients. The first US patient was enrolled into this Phase III global study in Rockville, MD.

    Comment?

  10. Supernus Pharmaceuticals Announces Third Quarter 2014 ResultsRead the original story

    Nov 12, 2014 | BioSpace

    The Company raises revenue guidance from approximately $105 million to a range of $115 million to $118 million for 2014 and reaffirms cash flow break even by end of year. Total revenue for the quarter, $52.5 million, includes $30.0 million in royalty monetization revenue.

    Comment?

  11. Supernus Pharmaceuticals To Present At Two Investor ConferencesRead the original story

    Nov 5, 2014 | BioSpace

    ROCKVILLE, Md., Nov. 4, 2014 -- Supernus Pharmaceuticals, Inc. a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present a Company overview and host investor meetings at the following investor conferences: Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has two marketed products for epilepsy, Oxtellar XRA and Trokendi XRA .

    Comment?

  12. Scheer Partners, Inc. Announces Full-Building Lease At 9708 Medical Center Drive In RockvilleRead the original story

    Oct 21, 2014 | BioSpace

    Shady Grove campus. The campus is owned and operated by BioMed Realty Trust, Inc., which owns more than 2 million rentable square feet of space in Maryland and more than 17 million rentable square feet worldwide.

    Comment?

  13. Emergent BioSolutions To Webcast Presentation At Healthcare ConferenceRead the original story

    Oct 20, 2014 | BioSpace

    ROCKVILLE, Md., Oct. 20, 2014 -- Emergent BioSolutions Inc. announced today that the company will be webcasting its presentation at the Credit Suisse 2014 Healthcare Conference in Phoenix, Arizona on Tuesday, November 11, 2014 at 8:00 AM Mountain. During the presentation, a member of the company's management team will provide a corporate overview, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance.

    Comment?

  14. Do-It-Yourself Flu Vaccine? Study Shows It Works, RevealsRead the original story

    Oct 9, 2014 | BioSpace

    Do-it-yourself flu vaccine? It could happen. Military folks who squirted vaccine up their noses were as well-protected as others who got it from health workers, a study found.

    Comment?

  15. Impressed With MacroGenics, Inc., Takeda Pharmaceutical Co. Ltd....Read the original story

    Sep 30, 2014 | BioSpace

    MacroGenics and Takeda Enter Second Strategic Alliance to Develop Multiple Additional DART Therapeutics ROCKVILLE, Maryland and OSAKA, Japan - September 29, 2014 - MacroGenics, Inc. MGNX, +2.77% and Takeda Pharmaceutical Company Limited jointly announced today that they have entered into a collaboration agreement to develop and commercialize up to four product candidates. These four research programs are in addition to MGD010, which was the subject of a prior agreement announced in May 2014.

    Comment?

  16. Supernus Pharmaceuticals Provides Business UpdateRead the original story

    Sep 23, 2014 | BioSpace

    ROCKVILLE, Md., Sept. 22, 2014 -- Supernus Pharmaceuticals, Inc. is providing the following business update in light of recent investor filings with the SEC: The Company reaffirms that it is on track to become cash flow breakeven by year-end, with a year-end cash balance of $75 million - $85 million.

    Comment?

  17. Spectrum Pharmaceuticals, Inc. Out-Licenses Rights For Greater China...Read the original story

    Sep 18, 2014 | BioSpace

    HENDERSON, Nev. & ROCKVILLE, Md.-- --Spectrum Pharmaceuticals, Inc. , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, and CASI Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a primary focus on China, announce the signing of license agreements whereby CASI has been granted exclusive rights to two of Spectrum Pharmaceuticals' commercial oncology drugs, ZevalinA Injection for intravenous use and MarqiboA for intravenous infusion, and a Phase 3 drug candidate, Captisol-Enableda Melphalan , for development and commercialization in China, including Taiwan, Hong Kong and Macau.

    Comment?

  18. Novo Nordisk A/S's Diabetes Drug Ryzodeg Effective In Phase 3b StudyRead the original story

    Sep 18, 2014 | BioSpace

    Ryzodeg is a new treatment option which provides proven glycaemic control, with fewer injections and reduced rates of hypoglycaemia compared to basal-bolus regimens," said Dr Helena Rodbard, the study's principal investigator and endocrinologist in Rockville, MD, USA. "This new treatment offers the potential for a simple alternative to basal-bolus for patients who require intensification of basal insulin regimens," she added.

    Comment?

  19. Emergent BioSolutions Awarded $29 Million Contract To Develop A Dry Formulation Of NuthraxRead the original story

    Sep 9, 2014 | BioSpace

    Emergent BioSolutions Awarded Contract To Develop A Dry Formulation Of Nuthrax, A Next Generation Anthrax Vaccine ROCKVILLE, Md.-- --Emergent BioSolutions Inc. announced today that it has signed a contract with the National Institute of Allergy and Infectious Diseases , part of the National Institutes of Health , to develop a dry formulation of NuThraxTM , also known as AV7909, the company's next generation anthrax vaccine candidate. This five-year contract, valued at up to $29 million, provides funding for manufacturing and non-clinical activities through the preparation of an Investigational New Drug application to the U.S. Food and Drug Administration.

    Comment?

  20. Emergent BioSolutions, MorphoSys AG Strike Prostate Cancer Pact Worth $183 MillionRead the original story

    Aug 20, 2014 | BioSpace

    Emergent BioSolutions And MorphoSys AG Sign License Agreement To C--Develop And Commercialize Prostate Cancer Drug Candidate ES414 ROCKVILLE, Md.

    Comment?

Rockville Job Listings
View or post Rockville job listings on Topix.
Rockville Real Estate
News, listings, and foreclosures in Rockville from Topix.
Rockville Mortgages
Find mortgage rates in Rockville on Topix.